Phantom Neuro is advancing implantable muscle interfaces that improve prosthetic hand control, targeting one of neurotech’s clearest paths to real-world adoption and near-term clinical impact.

China is assembling a vertically integrated neurotech stack, with state-backed companies advancing invasive BCIs, EEG platforms, neuromodulation, and imaging into structured clinical programs at growing scale.

Brain-computer interfaces are entering regulated human trials across invasive, minimally invasive, and non-invasive approaches, signalling a shift from experimental demos to real clinical pipelines.

Capital is concentrating around six invasive BCI leaders as investors back platforms with repeatable surgery, stable signals, and clear regulatory paths. The field is shifting from proof-of-concept to execution.

Tech billionaires are flooding into neurotech, backing brain-computer interfaces across invasive and non-invasive approaches. Their capital is accelerating progress while raising questions about control, incentives, and who shapes this technology.